C4 Therapeutics, Inc.
COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1
Last updated:
Abstract:
Compounds that degrade BRD9 or MTH1 via the ubiquitin proteasome pathway in a subject in need thereof for therapeutic applications are provided. The compounds provided have an E3 Ubiquitin Ligase targeting moiety (Degron) that is linked to a Targeting Ligand for BRD9 or MTH1.
Status:
Application
Type:
Utility
Filling date:
4 Mar 2021
Issue date:
1 Jul 2021